Saturday 23 December 2017 by FIIG Research Company factsheets

Valeant Pharmaceuticals International USD 5.50% 1-Nov-25 Senior Secured Notes Factsheet

THIS CONTENT IS SUITABLE FOR WHOLESALE INVESTORS ONLY

Valeant Pharmaceuticals International USD 5.50% 1-Nov-25 Senior Secured Notes Factsheet

Valeant Pharmaceuticals International, Inc. (Valeant, the Company) is a multinational, specialty pharmaceutical and medical device company that develops, manufactures, and markets a broad range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices, which are marketed directly or indirectly in over 100 countries. Valeant has diversity not only in its sources of revenue from its broad drug and medical device portfolio which includes contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices, but also among the therapeutic classes and geographies the company serves.

Valeant’s portfolio of products falls into three reportable segments: Bausch + Lomb/International, Branded Rx, and US Diversified Products. The Bausch + Lomb/International segment consists of sales in the US of pharmaceutical products, OTC products and medical device products, with a focus on Vision Care, Surgical, Consumer and Ophthalmology Rx products. This segment also accounts for the sales of branded pharmaceutical, branded generic pharmaceutical, OTC, medical device, and Bausch + Lomb products in Canada, Europe, Asia, Australia and New Zealand, Latin America, Africa and the Middle East. The Branded Rx segment consists of sales in the US of Salix, dermatological, branded pharmaceutical, branded generic pharmaceutical, OTC, medical device, dentistry and women’s health products. The US Diversified Products segment consists of sales in the US of pharmaceutical, OTC and medical device products in the areas of neurology and certain other therapeutic classes, including aesthetics (which includes the Obagi business, which the Company has entered into a definitive agreement to sell in July 2017).

  • View the Valeant Pharmaceuticals USD November 2025 Factsheet.External link - opens in a new window

Note: Access to the content will require a FIIG client login


Get your free copy of The Benefits of Corporate Bonds eBook

Get a copy of The Benefits of Corporate Bonds eBook

Subscribe to The WIRE newsletter

Sign up to a free weekly newsletter to get the latest investment news.